Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1 - Full Text View

Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000266

Purpose

The purpose of this study is to evaluate the safety and efficacy of flupenthixol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Flupenthixol	Phase II

Drug Information available for:

8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Flupenthixol Flupenthixol decanoate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Flupenthixol Treatment in Schizophrenic Cocaine Abusers

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Craving
Drug use
Psychiatric symptoms

Estimated Enrollment:	0
Study Start Date:	August 1994
Estimated Study Completion Date:	December 2001

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000266

Locations


United States, New York
	New York State Psychiatric Institute
	New York, New York, United States, 10032

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

New York State Psychiatric Institute

Investigators


Principal Investigator:	Herbert Kleber, M.D.	New York State Psychiatric Institute

More Information

Study ID Numbers:	NIDA-09236-1, P50-09236-1
First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000266
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders

Flupenthixol

Dopamine

Flupenthixol decanoate

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Additional relevant MeSH terms:

Neurotransmitter Agents

Tranquilizing Agents

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Physiological Effects of Drugs

Psychotropic Drugs

Central Nervous System Depressants

Dopamine Agents

Dopamine Antagonists

Antipsychotic Agents

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 29, 2008